38,007 Shares in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Acquired by HighTower Advisors LLC

HighTower Advisors LLC purchased a new stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 38,007 shares of the biopharmaceutical company’s stock, valued at approximately $448,000. HighTower Advisors LLC owned approximately 0.11% of Bellicum Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. grew its holdings in Bellicum Pharmaceuticals by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock valued at $1,029,000 after purchasing an additional 610 shares in the last quarter. American International Group Inc. grew its holdings in Bellicum Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 852 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Bellicum Pharmaceuticals by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 935 shares in the last quarter. ProShare Advisors LLC boosted its stake in Bellicum Pharmaceuticals by 14.9% during the 2nd quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 2,513 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Bellicum Pharmaceuticals by 30.4% during the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the last quarter. 55.91% of the stock is owned by institutional investors and hedge funds.

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at 9.74 on Friday. Bellicum Pharmaceuticals, Inc. has a 12 month low of $7.41 and a 12 month high of $23.11. The company has a 50-day moving average of $10.99 and a 200 day moving average of $11.35. The company’s market capitalization is $323.62 million.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the company posted ($0.61) earnings per share. Analysts forecast that Bellicum Pharmaceuticals, Inc. will post ($3.02) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/28/hightower-advisors-llc-purchases-shares-of-38007-bellicum-pharmaceuticals-inc-blcm.html.

A number of research analysts have commented on BLCM shares. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Finally, Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $26.20.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply